title: Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
abstract: BACKGROUND
  Overactive bladder syndrome (OAB) is a common condition affecting a significant number of working adults, resulting in increased healthcare utilization, reduced quality of life and decreased work productivity. The MATRIX study was a large, prospective, community-based, observational US study aimed at evaluating the impact of oxybutynin transdermal system (OXY-TDS). In this paper, we report on productivity findings among working adults in MATRIX.
  
  
  METHODS
  This study enrolled 2878 adults (aged > or =18 years) with symptoms of OAB from 327 practice sites throughout the US. All subjects received OXY-TDS (3.9 mg/day up to 6 months). Baseline versus end-of-study productivity was measured using the Work Productivity Questionnaire (WPQ). The WPQ includes a subset of questions from the Work Limitations Questionnaire (WLQ) and consists of four scales: (i) physical; (ii) time management; (iii) mental; and (iv) output demands. Overall productivity was measured by the work productivity index score (WPQ Index; a summary score based on scales) and work productivity loss score (WPLS; a measure of reduced output compared with healthy workers). Psychometric performance of the WPQ instrument is also reported, since this study represents the first use of the tool.
  
  
  RESULTS
  Of the participants, 52% were of working age (18-65 years) and 38.6% were employed. A total of 1112 working adults participated in MATRIX and were included in this analysis. They had a mean age of 52.4 years; 92.2% were female and 80.9% were Caucasian. Subjects who reported that they were most affected by OAB were also most impaired at work. After OXY-TDS treatment, participants experienced significant improvements in mean scores for all four WPQ scales (p < or = 0.0002) and the mean WPQ Index decreased from 8.2 to 5.5 (p < 0.0001). In addition, the WPLS decreased from 7.7% to 5.2% (p < 0.0001), indicating improvement in work function with OXY-TDS treatment.
  
  
  CONCLUSIONS
  OAB contributes to decreased work productivity due to job interruptions as well as fatigue. OXY-TDS may result in productivity improvement when patients receive 3.9 mg/day via twice weekly patch application for up to 6 months.
authors.affiliation: Doris N. Grandon Center for Health Economics and Outcomes Research, Jefferson School of Population Health, Philadelphia, Pennsylvania 19107, USA. laura.pizzi@jefferson.edu
authors.forename: Laura T
authors.initials: LT
authors.lastname: Pizzi
authors.forename: Amy
authors.initials: A
authors.lastname: Talati
authors.forename: Eric
authors.initials: E
authors.lastname: Gemmen
authors.forename: Naomi V
authors.initials: NV
authors.lastname: Dahl
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Bunz
authors.forename: Peter K
authors.initials: PK
authors.lastname: Sand
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D004526:Efficiency; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000191:economics*; D014937:Work / Q000706:statistics & numerical data*
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin